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Poly(butylcyanoacrylate) nanoparticles were prepared by dis-
persion polymerization (DP) and emulsion polymerization (EP)
of n-butyl cyanoacrylate monomer. The particles were character-
ized by infrared spectroscopy, differential scanning calorimetry,
X-ray diffractometry and transmission electron microscopy. Par-
ticle properties such as size and zeta potential were determined
for nanoparticles prepared by DP and EP techniques and com-
pared. EP technique resulted in a low particle size compared to
the DP. A high zeta potential was observed for nanoparticles
prepared by the DP method. Incorporation of methotrexate re-
sulted in a decrease in zeta potential in both types of nanopar-
ticles, the decrease being greater in DP nanoparticles. Effect of
experimental variables such as monomer concentration, poly-
merization time and temperature on drug entrapment and par-
ticle size was studied. Both types of nanoparticles showed an in-
crease in drug entrapment with increased monomer concentra-
tions. Variable polymerization time did not influence the drug
entrapment of EP nanoparticles. Polymerization at 60 ± 2 °C re-
sulted in a decrease of drug entrapment and a great increase in
the particle size of both types of nanoparticles. In vitro drug re-
lease studies showed a comparatively high release of methotre-
xate from DP nanoparticles suggesting the channelizing effect of
dextran chains incorporated into nanoparticles during polymer-
ization. Though the release profiles of nanoparticles appeared
similar, a significant difference in release rates was found for DP
and EP nanoparticles in 0.1 mol L–1 HCl and pH 7.4 phosphate
buffer (p < 0.01). Drug release data indicate that the release of
methotrexate from DP and EP nanoparticles followed Fickian
diffusion in 0.1 mol L–1 HCl, while the mechanism was found
anomalous in pH 7.4 phosphate buffer. An effort was also made
to critically correlate the properties of nanoparticles synthesized
by the above two techniques, and emphasize the importance of
these characteristics in targeted drug delivery.
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Poly(butylcyanoacrylate) (PBC) nanoparticles have gained increasing interest in the
drug delivery for pharmaceutical and medical applications. The butyl cyanoacrylate
monomer is polymerized by anionic radical polymerization in aqueous HCl solution at
a low pH in the presence of a stabilizer (1). By controlling the experimental parameters,
nanoparticles of definite size and polydispersity can be obtained. The reaction variables
such as pH and monomer concentration have significant influence on the properties of
the particles formed (2). The size and molecular mass distribution of polymer particles
were found to vary with pH (3). This is due to rapid polymerization above pH 5.0, re-
sulting in larger particles with broad multimodal molecular mass distributions. Behan et
al. (4) studied the effect of temperature and pH on particle formation, and observed an
increase in primary particle production with both pH and temperature. Monomer reac-
tivity is also important, as the change in reactivity of the monomer obtained from different
sources may lead to variability in the final particle size. Muller et al. (5) observed differ-
ences in the size of cyanoacrylate nanoparticles when monomers from different sources
were used.
Several drugs such as betaxolol chlorhydrate (6), hematoporphyrin (7), primaquine
(8) and doxorubicin (9) were either adsorbed or incorporated into the poly(alkylcyano-
acrylate) nanoparticles by different techniques. However, the method of preparation of
drug-free nanoparticles was almost similar in all cases. The general method of prepara-
tion followed the dispersion polymerization, which includes the addition of cyanoacry-
late monomer into the aqueous acidic medium containing a stabilizer (4, 9). To date, lit-
tle attention has been paid to studying the effect of the polymerization technique on the
properties of particles formed, and only little information was found in the literature on
emulsion polymerization of n-butyl cyanoacrylate. In addition, no studies on the effect
of experimental variables on the entrapment efficiency of poly(butylcyanoacrylate) na-
noparticles have been reported which is an essential optimization parameter. Particle
properties such as size and surface characteristics become considerably important when
the nanoparticles are intended for targeted delivery either by parenteral or by oral route
(10, 11). Jani and coworkers (12, 13) observed a high uptake of smaller polystyrene parti-
cles of up to 500 nm, and a reduced uptake of larger particles up to 1 m by the gut asso-
ciated lymphoid tissue, after oral administration in rats. Surface charge of the delivery
system plays an important role, especially when delivering drugs to the lymphatic system,
where the particulate uptake is limited by the barrier properties of the target system,
since the negatively charged interstitium preferentially allows particles of similar charge
(anionic) rather than oppositely charged (cationic) particles (14, 15). These particle pro-
perties could be expected to vary with the type of polymerization employed, owing to
their different mechanistic aspects. Emulsion polymerization possesses some inherent
advantages, such as a high rate of polymerization and formation of a high molecular
mass polymer of smaller particle size (16). Hence an attempt was made to synthesize
poly(butylcyanoacrylate) nanoparticles by both the dispersion polymerization (DP) and
emulsion polymerization (EP) techniques using methotrexate as a model drug and to
compare the properties of nanoparticles obtained.
Methotrexate is an antineoplastic agent widely used in the treatment of lymphobla-
stic leukemia, non-hodgkins lymphoma and osteogenic sarcoma (17). Owing to its struc-
tural similarity with dihydrofolate, it competitively inhibits dihydrofolate reductase,
thereby preventing the conversion of dihydrofolate to tetrahydrofolate resulting in cell
104
L. Harivardhan Reddy and R. S. R. Murthy: Influence of polymerization technique and experimental variables on the particle
properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles, Acta Pharm. 54 (2004) 103–118.
death. Poly(butylcyanoacrylate) nanoparticles could be beneficial carriers in targeting
anticancer agents such as methotrexate for cancer therapy, especially to the lymphatic
system, since these particles possess some prerequisite characteristics that facilitate lym-
phatic uptake such as anionic charge (5), hydrophobicity (18) and controlled particle size
(2). In the present communication, PBC nanoparticles were synthesized by the DP and
EP techniques and their influence on particle properties such as size and zeta potential
were studied. The effect of experimental variables, such as monomer concentration,
polymerization time and temperature, on entrapment efficiency of nanoparticles pre-




n-Butyl cyanoacrylate monomer and methotrexate (MT) were obtained from Sun
Pharmaceutical Industries Limited (India). Dextran 70 (molecular mass 70,000) was
kindly supplied by Claris Life Sciences Limited (India). Poloxamer 188 was purchased
from Sigma (USA). All other chemicals used in the study were of analytical grade. Water
used in all studies was distilled and filtered through 0.22 m nylon filter before use.
Synthesis of poly(butylcyanoacrylate) (PBC) nanoparticles
PBC nanoparticles containing methotrexate (MPBC) were synthesized by both the
dispersion polymerization and emulsion polymerization techniques. In the DP techni-
que, the cyanoacrylate monomer was added dropwise into the polymerization medium
under stirring at 700 rpm. The polymerization medium containing the drug was pre-
pared as follows. Methotrexate and dextran 70 (0.1%, m/V) were dissolved in 0.6 mL of
0.1 mol L–1 NaOH solution, and the volume was made up to 10 mL with 0.01 mol L–1
HCl. The final pH of the polymerization medium was around 3. Stirring was continued
after monomer addition for 3 h, and then the dispersion was neutralized to pH 7.0 with
phosphate buffer (PB) containing NaOH (pH 7.4).
In the EP technique, the monomer was added dropwise into the polymerization me-
dium containing methotrexate and Poloxamer 188 (0.5%, m/V) and it was proceeded as
for the dispersion polymerization.
Estimation of methotrexate in MPBC nanoparticles
The nanoparticulate dispersion was centrifuged at 15000 rpm for 30 min in a cool-
ing centrifuge (Remi C 24, Remi, India). The supernatant was decanted and the sedi-
ment was washed thrice with water and lyophilized. Washing of the nanoparticles was
done in order to determine their actual entrapment efficiency. The nanoparticles obta-
ined after lyophilization were weighed and dissolved in methanol and the solutions
were analyzed in a UV-Visible spectrophotometer (Hitachi U 2000, Japan) at 303 nm.
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Characterization of nanoparticles
Infrared spectroscopy. – Infrared spectra of the monomer and nanoparticles were re-
corded in KBr on a Shimadzu Fourier transform infrared spectrophotometer (Shimadzu,
Japan).
Differential scanning calorimetry (DSC). – DSC analysis was carried out on a Differen-
tial Scanning Calorimeter (Mettler Toledo, Switzerland) at a heating rate of 10 °C per
minute in the range of 50 to 350 °C.
X-ray diffractometry (XRD). – X-ray diffraction studies of the nanoparticles were per-
formed using a Rigaku D max III (Rigaku, Japan) X-ray diffractometer with a horizontal
goniometer. The samples were placed in the sample holder and scanned at a rate of 3°
per minute.
Transmission electron microscopy (TEM). – TEM photographs were taken using a Phi-
lips Technai-20 transmission electron microscope (Philips, The Nedherlands). The nano-
particles were dispersed in water and one drop of the diluted dispersion was placed on a
200-mesh carbon coated copper grid. 2% uranyl acetate was used as a staining agent.
Particle size analysis. – The particle size analysis was performed by dynamic light
scattering using a Malvern Hydro 2000 SM particle size analyzer (Malvern Instruments,
UK). The aqueous nanoparticulate dispersion was added to the sample dispersion unit
containing a stirrer and was stirred in order to minimize the inter-particle interactions,
and the laser obscuration range was maintained between 10–20%. The analysis was per-
formed thrice and the average value was taken.
The number of particles was calculated by the following equation (19):
Np = 6M0 Xm/  D3n
where Dn is the average diameter of the nanoparticles obtained from the dynamic light
scattering, Xm is fractional conversion, M0 is the initial concentration of the monomer in
the polymerization medium (g L–1),  is the polymer density (g L–1) and Np is the num-
ber of particles per mL.
Zeta potential measurement. – Zeta potential of the PBC and MPBC nanoparticles pre-
pared by both DP and EP methods was measured in a Malvern Zetasizer 3000 HSA (Mal-
vern Instruments, UK). Nanoparticles were dispersed in various media, such as 0.001
mol L–1 HCl, 0.9% saline (154.0 mmol L–1), phosphate buffer pH 7.4 (3.85 mmol L–1 di-
sodium hydrogen phosphate and 1.4 mmol L–1 potassium dihydrogen phosphate) and
tris buffer pH 8.0 9.99 mmol L–1 tris(hydroxymethyl)aminomethane, and the zeta po-
tential was measured.
In vitro drug release studies
The release of methotrexate from MPBC nanoparticles prepared by both DP and EP
methods was observed in 0.1 mol L–1 HCl and in pH 7.4 PB. The aqueous nanoparti-
culate dispersion was placed in a cellulose dialysis bag (6) (cut-off 5000, Hi-Media, In-
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dia), which was then sealed at both ends. The dialysis bag was dipped into the receptor
compartment containing dissolution medium, which was stirred continuously at 100 rpm
maintained at 37  2 °C. The receptor compartment was closed to prevent evaporation of
the dissolution medium. Samples were withdrawn at regular time intervals and the
same volume was replaced with fresh dissolution medium. The samples were measured
at 307 nm from 0.1 mol L–1 HCl and those from pH 7.4 PB at 299 nm. All experiments
were repeated thrice and the average values were taken. The release profiles obtained
were subjected to the t-test and the level of significance was determined.
RESULTS AND DISCUSSION
Polymerization of n-butyl cyanoacrylate
n-Butyl cyanoacrylate was polymerized by two techniques, the dispersion polymer-
ization and emulsion polymerization. Polymerization by DP and EP techniques both in-
volve the basic mechanism of anionic radical polymerization initiated by hydroxyl radi-
cals generated in the polymerization medium. The DP nanoparticles had an average
particle size of 318 nm with a broad particle size distribution, while EP nanoparticles
showed an average particle size of 178 nm with a narrow particle size distribution.
However, both types of nanoparticles exhibited monomodal particle size distribution.
The difference in the particle size and distribution pattern may be due to different me-
chanistic events during the polymerization.
During dispersion polymerization, the hydroxyl radicals generated in the polymer-
ization medium initiate the monomeric units to form oligomers, which grow in size till
they attain a critical molecular mass (CMM). Above the CMM, the solubility of oligo-
mers reduces in the aqueous phase, resulting in precipitation to form primary polymer
particles (also termed homogeneous nucleation). The newly formed primary particles
further absorb monomers from larger monomer droplets and polymerize to grow in size
(4). Hence, the process is also called coagulative nucleation. At this stage, the stabilizer
(dextran 70) covers the particle surface and prevents further aggregation by steric repul-
sion resulting in stabilized nanoparticles.
In the case of emulsion polymerization at surfactant (Poloxamer 188) concentration
above the critical micellar concentration (CMC), the micelles take up monomers to form
swollen structures. The entry of hydroxyl radicals into the monomer swollen micelles
initiates polymerization, resulting in the formation of primary polymer particles. These
primary particles are essentially stabilized by the surfactant (20). The monomer remain-
ing in larger droplets diffuses into primary particles, enhancing the swelling of particles.
Further growth of particles starts with the entry of the radical into the particle, which
continues to grow by propagation with the monomer. When the free radical enters a par-
ticle, the polymerization is initiated and continues until it is terminated by the entry of
another radical into the particle. Thus, it is possible for a molecule to grow to a very
high molecular mass before the radical is terminated. This process occurs simultaneou-
sly in a large number of particles, and as the particles are isolated in the medium by the
intervening aqueous phase, a growing polymer molecule in one particle cannot termi-
nate its counterpart in another particle. Hence, the overall rate of polymerization is high
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(16). The high degree of compartmentalization of the polymerization locus by the
surfactant contributes to high monomer conversion and a smaller particle size. From the
data of Np (number of particles per mL) calculated from the particle size measurement
data, it is evident that for a given quantity of monomer, the emulsion polymerization
method generated more particles due to the high degree of compartmentalization of the
polymerization locus by the surfactant (Poloxamer 188), thereby creating a larger num-
ber of nucleation sites, resulting in the formation of smaller particles. In the case of dis-
persion polymerization, the primary particles are generated from the aggregated oligo-
meric units, and swelling of these particles with the monomer and further polymerization
lead to larger particles compared to EP, where the particles are generated from monomer
swollen micelles. The number of particles per mL (Np) calculated from the particle size
analysis data for DP and EP nanoparticles was found to be in the order of 1.92  1011 and
5.603  1011, respectively. The transmission electron micrograph of nanoparticles reveals
their spherical nature (Fig. 1).
Incorporation of methotrexate into PBC nanoparticles
Methotrexate was incorporated into the DP and EP nanoparticles by its dissolving
in polymerization medium prior to addition of the monomer. The effect of experimental
variables such as monomer concentration, polymerization time and polymerization tem-
perature on the particle size and entrapment of MT was studied. Monomer concentra-
tions studied were in the range of 1% (m/V) to 3% (m/V). The entrapment efficiencies of
nanoparticles synthesized by DP and EP techniques did not vary significantly. Increase
in monomer concentration resulted in a progressive increase in entrapment efficiency of
the nanoparticles prepared by both DP and EP methods (Table I). In the range of concen-
tration studied by both methods, high entrapment efficiency was obtained with 3%
(m/V) monomer (86.0% and 87.4% for DP and EP methods, respectively), while low en-
trapment efficiency with 1% (m/V) monomer (42.4% and 43.1% for DP and EP methods,
respectively). Thus, the choice of monomer concentration is critical with respect to the fi-
nal entrapment efficiency and constitutes a suitable variable for obtaining nanoparticles
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Fig. 1. Transmission electron micrograph of poly(butylcyanoacryla-
te) nanoparticles synthesized by emulsion polymerization. The pho-
tograph was taken at 50 000× magnification.
with required drug entrapment. On the other hand, DP nanoparticles showed a great in-
crease in particle size (i.e., 318 nm for 1% (m/V) monomer and 474 nm for 3% (m/V)
monomer, respectively), while EP nanoparticles did not show much variation in size
with increasing monomer concentration. Increase in the size of DP nanoparticles with
monomer concentration can be attributed to particle agglomeration due to the reduced
effective concentration of the stabilizer (dextran 70) required to stabilize the polymer
particles formed. In the case of EP nanoparticles, at poloxamer 188 concentration above
CMC, the micelles can accommodate a higher quantity of monomer (within the mono-
mer concentrations used in the study) and their polymerization results in particles of an
almost uniform size. In this case, emulsion polymerization seems to be a better method
of nanoparticle preparation where the particle size is not compromised for drug entrap-
ment at varying monomer concentrations.
Following the increase in polymerization time, a slight increase in entrapment effi-
ciency of DP nanoparticles prepared with 3% (m/V) monomer was observed, exhibiting
maximum entrapment efficiency of 91.7% after 24 h (Table II). This may be attributed to
the high monomer to polymer conversion with time, leading to an increase in the
amount of the polymer formed, thereby incorporating a larger amount of drug. In con-
trast, the EP nanoparticles did not show much increase in entrapment efficiency with
time, indicating a rapid nanoparticle formation and drug entrapment. However, the size
of both DP and EP nanoparticles remained unchanged with time.
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Table I. Entrapment efficiency and the mean size of nanoparticles prepared by the dispersion
























Increase in polymerization temperature from 37  2 °C to 60  2 °C led to reduced
entrapment efficiency of nanoparticles synthesized by both DP and EP methods (Table
III). This may be attributed to drug leaching due to higher permeability of nanoparticles
at high temperature (60  2 °C). In addition, a great increase in size was found for both
types of nanoparticles at 60  2 °C. Fig. 2 depicts the size distribution pattern of nano-
particles at the two different temperatures studied. Both types of nanoparticles showed
a broader size distribution and a clear shift of size curves towards the larger particle di-
ameter at 60  2 °C compared to that at 37  2 °C, strongly supporting particle instability
and coagulation. The size of DP nanoparticles increased from 318 nm at 37 ± 2 °C to 342
nm at 60 ± 2 °C, while the size of EP nanoparticles increased from 178 nm at 37 ± 2 °C to
305 nm at 60 ± 2 °C. At higher temperatures, there is a possibility of inter-particle colli-
sions and particle aggregation due to the increase in the kinetic energy of the system,
leading to a large particle size, similar to that reported by Douglas et al. (2). The second
possibility contributing to the larger particle size in emulsion polymerization compared
to the dispersion polymerization at 60 ± 2 °C may be the higher dehydration of propyl-
ene oxide (PO) and ethylene oxide (EO) blocks within the poloxamer 188 molecule facili-
tating aggregation. This shows that no advantage is gained at a higher polymerization
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Table II. Entrapment efficiency and the mean size of nanoparticles prepared by the dispersion
















Table III. Entrapment efficiency of nanoparticles prepared by the dispersion polymerization and






Dispersion polymerization 37  2 86.0
60  2 78.1
Emulsion polymerization 37  2 87.4
60  2 80.2
temperature over ambient temperature with respect to both drug entrapment and the
size of nanoparticles. The optimal parameters of polymerization for the formation of
nanoparticles with high entrapment efficiency were found to be 3% (m/V) monomer
polymerized at 37  2 °C for 24 hours for dispersion polymerization, and polymerization
of 3% (m/V) monomer at 37  2 °C for 4 h for emulsion polymerization.
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Fig. 2. Comparison of size distri-
bution curves of poly(butylcyano-
acrylate)nanoparticles synthesized
by dispersion polymerization (DP)
and emulsion polymerization (EP)
at two different temperatures
 EP 37 ± 2 °C,  EP 60 ± 2 °C,
 DP 37 ± 2 °C,  DP 60 ± 2 °C.




The infrared spectrum of the poly(butylcyanoacrylate) nanoparticles (Fig. 3) shows
C-H (str) at 2957 cm–1, and C-H (def) at 1461 cm–1. The characteristic CN (str) of the
polymer was observed at 2200 cm–1. A prominent peak at 1750.3 cm–1 corresponds to
C=O (str), and C-O (str) was observed at 1259.4 cm–1. This indicates complete polymer
formation with all functional groups related to its structure. The spectrum did not show
the presence of aromatic peaks observed in the spectrum of the monomer (Fig. 3), which
may be due to impurities or polymerization inhibitors added in the monomers, indicat-
ing their loss during the purification stage.
DSC analysis was performed for both PBC and MPBC nanoparticles. PBC nanopar-
ticles showed a glass transition temperature (Tg) of 192.9 °C, and the 	H value of 1230
mJ (Fig. 4). The 	H value in the case of MPBC nanoparticles was shifted to 1753 mJ, and
the Tg was found to be 186.7 °C.
X-ray diffraction studies of the nanoparticles revealed the amorphous nature of the
polymer, since no characteristic peaks (Fig. 5) were observed to reveal its crystallinity.
The zeta potential of nanoparticles prepared by both DP and EP methods was deter-
mined in different media, such as 0.001 mol L–1 HCl, 0.9% saline, phosphate buffer pH
7.4 and tris buffer pH 8.0 (Table IV). The zeta potential of nanoparticles prepared by
both methods was found to increase with pH. The highest zeta potential was found in
tris buffer pH 8.0, and the lowest in 0.001 mol L–1 HCl. The results were in agreement
with those reported by Muller et al. (5) for alkyl cyanoacrylate nanoparticles. This is due
to the lower degree of dissociation of free acrylic acid groups of the polymer at low pH
values. A considerable difference in zeta potential was observed for nanoparticles pre-
pared by DP and EP methods. EP nanoparticles exhibited a considerably lower zeta po-
tential in all the media compared to DP nanoparticles. The difference in the zeta poten-
tial of DP and EP nanoparticles could be explained on the basis of previous reports.
Douglas et al. (21) reported the presence of residual amounts of dextran in cyanoacrylate
nanoparticles in the bulk as well as at the surface. A similar observation was reported by
Edman et al. (22) in the development of polyacryl dextran biodegradable microparticles.
High zeta potential values observed for the nanoparticles prepared by the DP method
are attributed to the contribution of charge by dextran 70 (dextran-O–), adsorbed onto
the nanoparticle surface. This is not the case of EP nanoparticles prepared in the pres-
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Table IV. Zeta potential values (mV) of PBC and MPBC nanoparticles prepared by the dispersion
polymerization and emulsion polymerization techniques
Dispersion medium PBC (DP) PBC (EP) MPBC (DP) MPBC (EP)
0.001 mol L–1 HCl –3.7 –0.5 –0.9 1.0
0.9% saline –11.9 –3.2 –2.5 –2.8
phosphate buffer pH 7.4 –30.4 –5.1 –3.3 –4.6
tris buffer pH 8.0 –42.8 –27.5 –15.2 –21.0
PBC – poly(butylcyanoacrylate) MPBC – methotrexate-loaded poly(butylcyanoacrylate)
DP – dispersion polymerization EP – emulsion polymerization
ence of nonionic surfactant Poloxamer 188. The EP nanoparticles were surfactant stabi-
lized during the polymerization, and hence the possibility of a masking effect on particle
charge due to surfactant adsorption cannot be ruled out. Such decrease in zeta potential
after coating with block copolymers was also observed by Hawley et al. (23) in poly-
(DL-lactide-co-glycolide) nanospheres. Incorporation of methotrexate into nanoparticles
showed a decrease in zeta potential values in both cases (Table IV), the decrease being
high in DP nanoparticles. During the polymerization process, adsorption of MT onto the
nanoparticle surface is possible, contributing to masking the polymer charge. A signifi-
cant decrease in the zeta potential of nanoparticles prepared by the DP method after
drug incorporation in comparison to those prepared by the EP method, further strength-
ens the aspect of dextran presence on the particle surface, whose charge is masked by
the adsorbed drug, contributing to the overall great decrease of the zeta potential.
Nanoparticles prepared by the DP method having a high zeta potential would be
advantageous, especially in drug delivery to the lymphatic system, since the negatively
charged hydrophobic particles undergo increased uptake by the lymphatic capillaries (14,
15). Owing to their hydrophobicity, these particles undergo opsonization and uptake by
macrophages after intravenous administration, and may further result in increased lym-
phatic concentration. On the other hand, the surfactant stabilized nanoparticles (EP
nanoparticles), because of their hydrophilic surface, may experience steric stabilization
and dysopsonization, and thus show an increased blood residence time. This facilitates
an increased half-life of the drug (24) and also enhances cellular uptake of nanoparticles,
preferentially into malignant tissues due to the leaky nature of the endothelium (25).
The adsorption of dextran molecules onto the surface of nanoparticles may influ-
ence the in vivo particle distribution. Yoshikawa et al. (26) observed an increase in lymph
affinity of high molecular mass (40 and 70 kD) fluorescent labeled dextrans dissolved in
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mixed micellar solution. Similarly, Takakura and coworkers (14, 15) reported an increase
in thoracic lymph concentrations of anionic dextran conjugates of mitomycin C, com-
pared to that of the free drug. Similarly, the adsorption of dextran molecules on the sur-
face of PBC nanoparticles could be advantageous in lymphatic drug delivery. However,
the above hypothesis needs animal experimentation to reach definite conclusions, and
related studies are under progress in our laboratory.
In vitro drug release studies
In vitro release of methotrexate from MPBC nanoparticles prepared by both DP and
EP methods was studied in 0.1 mol L–1 HCl and in pH 7.4 PB (Fig. 6). The drug release at
various pH provides a basic idea of drug release in physiological systems and in intra-
cellular regions with acidic pH.




) = log k + n log t
where Mt/M
 is the fractional amount of drug released, k is the diffusional constant and
n is the diffusional exponent. The results of kinetic analysis are given in Table V.
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Fig. 5. X-ray diffraction pattern of: (a)
poly(butylcyanoacrylate) synthesized
by dispersion polymerization, (b) poly-
(butylcyanoacrylate) synthesized by
emulsion polymerization. The diffrac-
tograms indicate the amorphous nature
of the polymer.
The release of methotrexate from nanoparticles prepared by DP and EP methods
followed Fickian diffusion in 0.1 mol L–1 HCl, while the mechanism was found anoma-
lous in pH 7.4 PB.
Both types of nanoparticles showed faster drug release in 0.1 mol L–1 HCl than in
pH 7.4 PB. Though the release profiles appeared similar in all media, a significant differ-
ence in release rates was observed. The t50 (time taken for 50% drug release) values cal-
culated for DP nanoparticles were 2.2 h in 0.1 mol L–1 HCl and 5 h in pH 7.4 PB. For EP
nanoparticles, the t50 values were 2.6 h and 3.9 h in 0.1 mol L–1 HCl and pH 7.4 PB, re-
spectively. The statistical analysis of release rates showed a significant difference in t50
values of both types of nanoparticles in all media (p < 0.01). A comparatively faster re-
lease of MT from DP nanoparticles in 0.1 mol L–1 HCl suggests the channelizing effect of
dextran chains incorporated into the nanoparticle matrix during polymerization. The re-
lease of methotrexate from MPBC nanoparticles in pH 7.4 PB showed a different trend,
where higher drug release was observed from EP nanoparticles (77.4%) than from DP
nanoparticles (65.7%). The lower drug release shown by DP nanoparticles in pH 7.4 PB
than the EP nanoparticles may be due to particle agglomeration, as reported by Som-
merfeld et al. (28) in the case of poly(butylcyanoacrylate) nanoparticles in pH 7.4 phos-
phate buffered saline, suggesting an increase in diffusional path length of the drug, re-
sulting in slow drug release.
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Table V. Diffusion exponent for MPBC nanoparticles obtained from the release plots of
log (Mt/M) versus log t in various media
Nanoparticle type Release medium n
DP 0.1 mol L–1 HCl 0.44
DP phosphate buffer pH 7.4 0.72
EP 0.1 mol L–1 HCl 0.50
EP phosphate buffer pH 7.4 0.60
DP – dispersion polymerization






















Fig. 6. Release profiles of methotrexate from
poly(butylcyanoacrylate) nanoparticles in
various media (mean  SD, n = 3).  DP 0.1
mol L–1 HCl,  DP pH 7.4 PB,  EP pH 7.4
PB,  EP 0.1 mol L–1 HCl.
From the release pattern shown by nanoparticles, it could be expected that the
nanoparticles exhibit slow release till they reach the intracellular site and then release
the drug at a faster rate in the endosomal acidic pH, leading to high intracellular drug
concentrations similar to the pH sensitive liposomes reported by Horwitz et al. (29).
Such release pattern can be exploited in intracellular drug delivery and in the treatment
of tumors, where an increased intracellular drug concentration is required.
CONCLUSIONS
Emulsion polymerization of n-butyl cyanoacrylate resulted in nanoparticles of
smaller size, compared to the dispersion polymerization owing to their different mecha-
nistic events. High zeta potential values shown by DP nanoparticles reveal their useful-
ness in targeting drugs on the lymphatic system, a limiting barrier for cationic particles,
especially for delivering anticancer agents in the prevention of metastasis of cancer cells.
Such nanoparticles can also form a better delivery system for drug targeting through in-
testinal Peyer’s patches (PP), as PP were shown to take up small hydrophobic particles
with great affinity. The surfactant stabilized nanoparticles prepared by emulsion poly-
merization may be advantageous as a long circulating system in blood because of their
surface coverage by hydrophilic surfactant and also for targeting the malignant tissues.
This shows that variation in the polymerization technique produces particles with dif-
ferent properties, which can be exploited in drug delivery in different ways. The drug
release studies showed a significant difference in release rates in the media used in the
study and the release pattern obtained may be advantageous in intracellular delivery of
nanoparticles. Finally, the nanoparticles showed prolonged drug release, indicating its
usefulness in controlled delivery applications.
Acknowledgements. – The authors thank the University Grants Commission (UGC), New Delhi,
India, for funding this work.
REFERENCES
1. P. Couvreur, B. Kante, M. Roland, P. Guiot, P. Bauduin and P. Speiser, Polycyanoacrylate nano-
capsules as potential lysosomotropic carriers: preparation, morphological and sorptive proper-
ties, J. Pharm. Pharmacol. 31 (1979) 331–332.
2. S. J. Douglas, L. Illum, S. S. Davis and J. Kreuter, Particle size and size distribution of poly-
(butyl-2-cyanoacrylate) nanoparticles II. Influence of physicochemical factors, J. Colloid Interface
Sci. 101 (1984) 149–157.
3. N. Behan and C. Birkinshaw, Mechanism of polymerization of butyl cyanoacrylate in aqueous
dispersions, Macromol. Rapid Commun. 21 (2000) 884–886.
4. N. Behan, C. Birkinshaw and N. Clarke, Poly n-butyl cyanoacrylate nanoparticles: a mechanis-
tic study of polymerization and particle formation, Biomaterials 22 (2001) 1335–1344.
5. R. H. Muller, C. Lherm, J. Herbot, T. Blunk and P. Couvreur, Alkyl cyanoacrylate drug carriers:
I. Physicochemical characterization of nanoparticles with different chain length, Int. J. Pharm. 84
(1992) 1–11.
116
L. Harivardhan Reddy and R. S. R. Murthy: Influence of polymerization technique and experimental variables on the particle
properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles, Acta Pharm. 54 (2004) 103–118.
6. I. Marchal-Heussler, P. Maincent, M. Hoffman, J. Spittler and P. Couvreur, Antiglaucomatous
activity of betaxolol chlorhydrate sorbed onto different isobutyl cyanoacrylate nanoparticle pre-
parations, Int. J. Pharm. 58 (1990) 115–122.
7. N. Brasseur, D. Brault and P. Couvreur, Adsorption of hematoporphyrin onto polyalkyl cyano-
acrylate nanoparticles: carrier capacity and drug release, Int. J. Pharm. 70 (1991) 129–135.
8. R. Gaspar, V. Preat and M. Roland, Nanoparticles of polyisohexyl cyanoacrylate (PIHCA) as
carriers of primaquine: formulation, physico-chemical characterization and acute toxicity, Int. J.
Pharm. 68 (1991) 111–119.
9. C. Verdun, P. Couvreur, H. Vranckx, V. Lenaerts and M. Roland, Development of a nanoparticle
controlled-release formulation for human use, J. Control Rel. 3 (1986) 205–210.
10. L. H. V. Reddy and R. S. R. Murthy, Lymphatic transport of orally administered drugs, Ind. J.
Exp. Biol. 40 (2002) 1097–1109.
11. C. J. H. Porter, Drug delivery to the lymphatic system, Crit. Rev. Ther. Drug Carrier Syst. 14
(1997) 333–393.
12. P. Jani, G. W. Halbert, J. Langridge and A. T. Florence, The uptake and translocation of latex
nanospheres and microspheres after oral administration to rats, J. Pharm. Pharmacol. 41 (1989)
809–812.
13. P. Jani, G. W. Halbert, J. Langridge and A. T. Florence, Nanoparticle uptake by the rat gastroin-
testinal mucosa: Quantitation and particle size dependency, J. Pharm Pharmacol. 42 (1990) 821–826.
14. Y. Takakura, S. Matsumoto, M. Hashida and H. Sezaki, Enhanced lymphatic delivery of mito-
mycin C conjugated with dextran, Cancer Res. 44 (1984) 2505–2510.
15. Y. Takakura, M. Kitajima, S. Matsumoto, M. Hashida and H. Sezaki, Development of a novel
polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I.
Physicochemical characteristics and in vivo and in vitro antitumor activities, Int. J. Pharm. 37
(1987) 135–143.
16. F. A. Bovey, I. M. Kolthoff, A. I. Medalia and E. J. Meehan, Emulsion polymerization, Intersci-
ence publishers, New York 1955, pp. 1–22.
17. C. Dollery, Therapeutic Drugs, Churchill Livingstone Publishers, Edinburgh 1999, pp. M90–M96.
18. J. Kreuter, Physicochemical characterization of polyacrylic nanoparticle, Int. J. Pharm. 14 (1983)
43–58.
19. S. Bhawal, N. K. Pokhriyal and S. Devi, Translucent nanolatexes through emulsion polymeriza-
tion of ethyl acrylate, Eur. Polymer J. 38 (2002) 735–744.
20. R. G. Gilbert, Emulsion Polymerization: A Mechanistic Approach, Academic Press, London 1995,
pp. 1–25.
21. S. J. Douglas, L. Illum, S. S. Davis and J. Kreuter, Particle size and size distribution of poly-
(butyl-2-cyanoacrylate) nanoparticles II. Influence of stabilizers, J. Colloid Interface Sci. 103 (1985)
154–163.
22. P. Edman, B. Ekman and I. Sjoholm, Immobilization of proteins in microspheres of biodegrad-
able polyacryl dextran, J. Pharm. Sci. 69 (1980) 838–842.
23. A. E. Hawley, L. Illum and S. S. Davis, Lymph node localization of biodegradable nanospheres
surface modified with poloxamer and poloxamine block co-polymers, FEBS Lett. 400 (1997)
319–323.
24. S. M. Moghimi, A. C. Hunter and J. C. Murray, Long-circulating and target-specific nanoparti-
cles: Theory to practice, Pharmacol. Rev. 53 (2001) 283–318.
25. R. Duncan, Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR ef-
fect as a common gateway? Pharm. Sci. Tech. Today 2 (1999) 441–449.
117
L. Harivardhan Reddy and R. S. R. Murthy: Influence of polymerization technique and experimental variables on the particle
properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles, Acta Pharm. 54 (2004) 103–118.
26. H. Yoshikawa, K. Takada and S. Muranishi, Molecular weight dependence of permselectivity of
rat small intestinal blood-lymph barrier for exogenous macromolecules absorbed from lumen,
J. Pharmacobio. Dyn. 7 (1984) 1–6.
27. P. L. Ritger and N. A. Peppas, A simple equation for description of solute release. II. Fickian
and anomalous release from swellable devices, J. Control Rel. 5 (1987) 37–42.
28. P. Sommerfeld, U. Shroeder and B. A. Sabel, Long-term stability of PBCA nanoparticle suspen-
sions suggests clinical usefulness, Int. J. Pharm. 155 (1997) 201–207.
29. B. A. Horwitz, M. Shintizky, W. Kreutz and M. B. Yatwin, pH sensitive liposomes: possible clini-
cal implications, Science (Washigton DC) 210 (1980) 1253–1255.
S A @ E T A K
Utjecaj na~ina polimerizacije i eksperimentalnih varijabli na svojstva ~estica i
brzinu osloba|anja metotreksata iz nano~estica s poli(butilcijanoakrilatom)
LAKKIREDDY HARIVARDHAN REDDY i RAYASA RAMACHANDRA MURTHY
Prire|ene su nano~estice poli(butilcijanoakrilata) disperzijskom (DP) i emulzijskom
polimerizacijom (EP) n-butyl-cijanoakrilata. ^estice su karakterizirane IR spektroskopijom,
diferencijalnom pretra`nom kalorimetrijom, difraktometrijom X-zra~enjem i transmisijskom
elektronskom mikroskopijom. Uspore|ivana je veli~ina i zeta potencijal nano~estica do-
bivenih na oba na~ina. Nano~estice prire|ene EP metodom bile su manje nego ~estice
dobivene DP metodom, a ~estice prire|ene DP metodom imale su visoki zeta potencijal.
Uklapanje metotreksata smanjilo je zeta potencijal u obje vrste nano~estica, naro~ito u
DP nano~esticama. Prou~avan je utjecaj eksperimentalnih varijabli (koncentracija mono-
mera, vrijeme polimerizacije i temperatura) na uklapanje ljekovite tvari i veli~inu ~estica.
Pove}anje koncentracije monomera kod obje vrste ~estica pove}alo je uklapanje ljekovite
tvari. Produljenje vremena polimerizacije nije utjecalo na koli~inu uklopljenog metotre-
ksata u EP nano~esticama. Povi{enjem temperature na 60  2 C smanjilo se uklapanje, a
pove}ao promjer obje vrste nano~estica. In vitro studije pokazale su zna~ajno osloba|a-
nje metotreksata iz DP nano~estica, {to upu}uje na nastanak kanali}a uslijed ugradnje
lanaca dekstrana u nano~estice tijekom polimerizacije. Iako se profili osloba|anja meto-
treksata ~ine sli~nima, zna~ajne razlike izme|u DP i EP nano~estica uo~ene su u otopini
kloridne kiseline koncentracije 0,1 mol L–1 i fosfatnom puferu pH 7,4 (p  0,01). Osloba|anje
ljekovite tvari pratilo je Fickov zakon difuzije u 0,1 mol L–1 HCl, dok je u puferu pH 7,4
mehanizam bio anomalan. Poku{alo se dovesti u korelaciju svojstva nano~estica prire|e-
nih na oba na~ina i naglasiti va`nost tih svojstava u ciljanoj isporuci ljekovitih tvari.
Klju~ne rije~i: disperzijska polimerizacija, emulzijska polimerizacija, nano~estice, poli(butilcijano-
akrilat), svojstva ~estica, metotreksat, osloba|anje lijeka
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